Forbion’s largest raise to date will support venture- and growth-stage companies across Europe and North America
Fierce Biotech’s article “Forbion’s ‘landmark’ €2.3B fundraise to benefit 30 ‘high potential’ biotechs” reports on the record capital raised across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII.
Together, the funds are expected to finance approximately 30 high-potential biotech companies, with initial investments already completed. The article highlights strong demand from new and existing investors, including MN, PGGM, KfW Capital, the Kauffman Foundation and Eli Lilly and Company, and notes that the new total exceeds Forbion’s previous record raise in 2024.
Forbion Managing Partner and Co-Founder Sander Slootweg, explains that the new capital gives Forbion significant capacity to invest selectively in biotech companies developing paradigm-shifting treatments for areas of genuine unmet need. Fierce Biotech also highlights Forbion’s two decades of company building and investment, including its support for gene therapy company Beacon Therapeutics and small-molecule medicines company Gate Bioscience, as well as the firm’s broader role in advocating for a stronger and better-funded European biotech ecosystem.